In the Mood for Data

Dan Housman and Omer Saka of Roland Berger discuss how digital strategies for Target Product Profiling can create value and competitive advantage for life science organizations.

Watch the Novel Cohorts podcast with special guest Jeff Wessinger, General Manager & Vice President of PointClickCare.

Watch the latest Novel Cohorts podcast with special guest, Eze Abosi, Chief Growth Officer at Holmusk. Dan and Eze discuss the role of real-world data (RWD) to advance precision medicine in psychiatry and mental health care.

In this podcast Mitchell Goldburgh, SR. Director of Solutions – Enterprise Imaging & Advocate AI Services from NTT DATA, and Rob Hauser, the Chief Business & Analytics Officer from Vidence, discuss applications of datasets that extend oncology data from a large national cancer center with radiology studies and reports such as chest CT scans of lung cancer patients. The discussion explains why synthetic control arms and label expansion studies are important and explores how advanced oncology data can reduce the need to recruit patients into clinical trials. The panel also provides insight into the process to build new digital diagnostic tools based on radiomics data that are being developed to predict which patients will respond to personalized therapies. You will also learn about the multiple approaches NTT DATA has put in place to make the most of unstructured data within the NTT DATA environment including feasibility studies, abstraction, machine learning/AI, and annotation by radiologists.

Julie Krommenhoek, Vice President of Global Sales for IBM Watson Health, and Dan Housman, CTO from Graticule, discuss how the two companies are collaborating. Drawing on her extensive background in pharma research and real-world data, Julie shares how a partnering approach can solve the hard problems rare disease focused therapeutics companies face due to the limited volumes of patients they can track with RWD. The discussion explores a joint vision for creating and deploying algorithms to identify undiagnosed patients to support clinical trial recruitment or digital diagnostics to increase access to precision therapies. The podcast also explores how leveraging privacy preserving linking can extend claims data with other advanced patient data such as radiology, pathology, PROs, and genetic testing. These linked data sets can enable researchers even when analyzing small populations to generate necessary evidence to measure the value of new therapeutics on medical costs, outcomes, and patient experience in rare cohorts.

In this podcast Mitchell Goldburgh, Global Solutions Leader at NTT DATA Services, and Dan Housman, CTO at Graticule discuss NTT’s Advocate AI service and how their solution can efficiently and effectively address the challenges of aggregating data from multiple healthcare sites into a data cooperative — accelerating insights utilizing previously untapped resources (for example, medical images, and associated reports). Advocate AI’s rich data source and associated analytic tools enables Graticule to achieve the scale required to provide rapid feasibility analyses and help the industry address and answer complex healthcare questions today while opening up exciting possibilities for future innovation.

In this podcast Novo Nordisk researcher Dr. Kajsa Kvist and Dr. John Buse from the University of North Carolina at Chapel Hill (UNC Health) discuss how and why Novo Nordisk became an early participant of the National COVID-19 Collaborative (N3C), as a tool to study the pandemic. The Novo Nordisk patient analytics team led by Dr. Kvist is studying how COVID-19 affects patients with diabetes to learn how their products can help infected patients. The collaborators discuss the working model they established to leverage the strengths of academic and industry partners through the N3C.

In this podcast, Dan Housman and Craig Lipset discuss innovative and alternative approaches where Real World Data approaches are becoming increasingly integrated into clinical trials. They explore the increasing opportunity to electronically source real world data for clinical trials including integrating patient voices into consent and feedback of results. Craig shares a vision of how these new approaches can enable improvements that can lead to both better patient satisfaction and more efficient clinical research as a result.

In this podcast Dan Housman and Joy Alamgir discuss the importance and value of commercial:public collaborations that leverage real-time real world data to accelerate COVID-19 research efforts. Currently there is a limited understanding of the potential efficacy of existing therapies to treat and manage COVID-19. Opportunities to investigate research into the repurposing of existing therapies may be both clinically and cost effective.

In this podcast, Dan Housman and Giuliana Kotikela, Co-Founder and CEO of ChiKeey, a fashionable and functional wearable device discuss the utility of real-time biometrics and advanced real-world data and analytics to assess and analyze emotional wellness. Chikeey’s solution utilizes unique indicators to proactively identify potentially significant changes in mental health where individuals may benefit from earlier intervention either via support or therapies. With this perspective we will discuss future applications to support the next generation of clinical research and patient care via remote monitoring.